Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioCardia ( (BCDA) ) just unveiled an update.
On May 21, 2026, BioCardia reported preliminary open-label cohort results from its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial, presented at the EuroPCR conference in Paris by Dr. Amish Raval. The minimally invasive autologous cell therapy was well tolerated, with no treatment-emergent major adverse cardiac events and durable clinical benefits for patients with refractory angina who had exhausted standard therapies.
Patients in the trial, all already on guideline-directed medical therapy and prior revascularization as appropriate, showed an average 179-second improvement in exercise tolerance that persisted through two years of follow-up. Angina episodes fell by an average of 82% within six months, highlighting the potential of CardiAMP’s locally delivered cell therapy to address a large unmet need in chronic myocardial ischemia and reinforcing BioCardia’s positioning in next-generation cardiac therapeutics.
The most recent analyst rating on (BCDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
The score is held down primarily by very weak financial performance (no meaningful revenue, large losses, heavy cash burn and negative equity) and bearish technicals (price below key moving averages with negative MACD). Positive regulatory/clinical updates from the earnings call provide some support, but they are outweighed by immediate financing needs and execution risk to reach key trial and approval milestones.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global developer of cellular and cell-derived therapeutics targeting cardiovascular and pulmonary diseases. Its biotherapeutic platforms include the autologous CardiAMP and allogeneic CardiALLO cell therapies, supported by proprietary Helix and Morph delivery systems and the upcoming Heart3D fusion imaging platform.
The company focuses on treating severe cardiac conditions such as ischemic heart failure and chronic myocardial ischemia, with three cardiac clinical-stage product candidates in development. BioCardia also partners with other biotherapeutic developers to provide specialized delivery technologies, and its CardiAMP trials benefit from Medicare coverage for both treatment and control procedures.
Average Trading Volume: 161,834
Technical Sentiment Signal: Sell
Current Market Cap: $10.46M
For detailed information about BCDA stock, go to TipRanks’ Stock Analysis page.